Season 9 · Episode 2
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
OncLive® On Air · OncLive® On Air
June 12, 202311m 0s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.